Bladder cancer is the fifth most common cancer in the western male population, with an annual incidence of 20 cases per 100,000. The incidence in women is lower: about five cases per 100,000 are diagnosed annually (Raghavan et al., 1990) . Transitional cell carcinoma of the bladder is divided into two groups: (a) superficial (pTis, pTa, pTl) and (b) muscle invasive (pT2, pT3, pT4) disease. Most superficial bladder cancers are associated with a good prognosis, however 10-25% clinically progress to a more aggressive state, showing an increase in grade and/or infiltration into the muscle layer. pTl tumours invade the lamina propria and have a higher incidence of progression than pTa tumours, which are confined to the urothelium. Patients with muscleinvasive tumours usually present de novo and have a worse prognosis. Non-random chromosomal changes have been observed in bladder cancer, for example in cytogenetic studies monosomy of chromosome 9 has been reported (Gibas et al., 1984; Vanni & Scarpa, 1986; Smeets et al., 1987; Hopman et al., 1988) . Using restriction fragment length polymorphism analysis (RFLP), allelic loss of chromosomes 9, 11 and 17 in bladder cancer has been demonstrated (Tsai et al., 1990) . Abnormalities of chromosome llp appeared to be more frequent in invasive than in superficial tumours, and monosomy of chromosome 9 was not correlated with grade or stage. Loss of heterozygosity (LOH) of chromosome 17p occurred only in high-grade (G3) tumours (Olumi et al., 1990) . The p53 gene is considered the candidate tumoursuppressor gene on chromosome 17p, since in cancer development one of the two alleles is frequently lost and the remaining is mutated (Baker et al., 1989; Hollstein et al., 1991) . Recently, it has been suggested that p53 acts as a cell cycle control protein at the level of GI to S phase transition (Kastan et al., 1991; Livingstone et al., 1992; Yin et al., 1992) . The loss of this function may result in increased genetic instability (Yin et al., 1992) . In bladder cancer it has been shown, by means of subcloning and sequencing of exons 5-9, that 17p allelic loss is strongly associated with p53 mutation (9 out of 10 cases), and out of 18 invasive tumours 61a% had a p53 mutation . This association of p53 mutations and invasive tumours was confirmed in another study by using the technique of PCR-SSCP (Fujimoto et al., 1992) .
We studied p53 mutations in a group of 45 patients with bladder cancer, using PCR-SSCP analysis. Besides a correlation with grade and stage, we investigated the prognostic significnce of p53 mutations. Since p53 mutations are thought to be associated with genetic instability (Kastan et al., 1991; Livingstone et al., 1992; Yin et al., 1992) we also studied the correlation of p53 mutations and genetic instability evaluated by the frequency of allelic loss. Table I . Genomic DNA was extracted from stepsectioned tumours (> 70% tumour cells) (Miller et al., 1988) .
PCR-SSCP analysis PCR-SSCP analysis was performed to investigate p53 mutations in exons 5-8 (Orita et al., 1989) . The intron primers for amplification of exons 5-8 were: p53 MUTATIONS IN BLADDER CANCER Sequence analysis Direct sequencing of the double-stranded PCR products that showed a shift on the SSCP gels was performed as described previously (Kusukawa et al., 1990) . Amplified PCR products were purified using the magic PCR-preps DNA purification system (Promega). The PCR primers were used for sequencing in the ds-DNA cycle sequencing system (Life Technologies). Electrophoresis was performed on 6% polyacrylamide gels containing 7 M urea.
Restriction fragment length polymorphism The DNA probes used were as follows: chromosome 9q, EFD 126 (Nakamura et al., 1987) ; chromosome lip, H-ras (Pulciano et al., 1982) ; chromosome 16q, pV962 (Mansouri et al., 1988) and 79.2.23 (Bufton et al., 1986) ; chromosome 17p, 144D6 (Schwartz et al., 1988) ; chromosome 18q, 15.65 (Fearon & Vogelstein, 1990) . RFLP analysis was performed on the 24 patients from whom normal DNA was available (Poddighe et al., submitted) . The RFLP results were used to determine the frequency of allelic loss (FAL), also called fractional allelic loss (Vogelstein et al., 1989 Table I summarises the results of the PCR-SSCP and sequence analysis of the p53 gene in bladder tumours of 45 patients. Eight mutations were found in invasive tumours: three in exon 5, one in exon 6, one in exon 7 and three in exon 8. Seven out of the eight mutations found were point mutations, while one appeared to be a deletion of a G. leading to a frameshift. We found four transitions -two G to A, one A to G and one C to T -and three transversionsone C to G, one G to T and one A to T. In three patients with a superficial tumour a similar shift in the SSCP pattern of exon 6 was observed. One of these also showed loss of heterozygosity of chromosome 17p. After sequencing it appeared that the shift in the SSCP pattern was due to a silent alteration of CGA to CGG at codon 213. This polymorphism has been described previously (Mazars et al., 1992) . No mutations were found in the squamous cell carcinomas.
Correlation between tumour stage grade and p53 mutations All the p53 mutations were found in grade 3 tumours, as is shown in Table Ila ( P<0.001) . No mutations were found in the group of superficial tumours, while a p53 mutation was found in 8 out of 24 (33%) invasive tumours (P<0.001) ( Table Ilb) . This is in good agreement with previous observations Fujimoto et al., 1992) .
Relation between p53 mutations andfrequency of allelic loss As a measure of genetic instability, we used frequency of allelic loss (FAL). FAL was based on RFLP analysis using probes for chromosomes 9q, llp, 16q, 17p and 18q (Table  lIla) . LOH Fujimoto et al., 1992) . A p53 mutation was found in 8/24
(33%) of the invasive tumours, which were all grade 3. The p53 tumour-suppressor gene is known to be mutated in many types of cancer (Hollstein et al., 1991) and during tumour progression one of the two alleles is often lost, resulting in a reduction of growth control (Baker et al., 1989) . However, some p53 mutations are known to be dominant negative: the proten produced by the mutated alele has the ability to bind and inactivate the remaining wild-type product (Vogelstein, 1990) . In our study we did not find any mutation without LOH of 17p. On the contrary, one patient with 17p LOH had no p53 mutation. It could be that the mutation is outside the region of the p53 gene studied or that a second locus disnct from p53 is involved (Saxena et al., 1992) .
Wild-type p53 has been sugste to be a cell cycle control protein, since progression from GI to S phase is often blocked in cells expressing high levels of this protein (Kastan et al., 1991; Livingstone et al., 1992; Yim et al., 1992) . It has been shown that cells without wild-type p53 protein fail to show growth arrest (when subjected to conditions unfavourable for the S phase completion) and gene amplification occurs (Yin et al., 1992) , which can be considered a form of genetic instability. As p53 mutations are known to occur in bladder cancer Fujimoto et al., 1992) , we used frequency of allelic loss as an indicator of genetic instability (Vogestein et al., 1989) . The high frequency of allelic loss found in tumours with a p53 mutation (55.8%, P<0.05) suggests a correlation with genetic instability. This increase in allelic loss in tumours with a p53 mutation could be explained by an altered GI-S cell cycle checkpoint, which can be the result of the loss of the wild-type p53 function. The loss of certain alleles, e.g. those harbouring tumoursuppressor genes, could provide selective advantages during tumour progression by generating variants with a more aggressive phenotype (Fearon & Vogelstein, 1990) . FAL showed no significant correlation with grade or stage.
In breast cancer p53 mutations are inversely correlated with survival (Allred et al., 1993) . This study is the first report investigating the prognostic signi of p53 mutations in bladder cancer. The results demonstrate that p53 mutations are an unfavourable prognostic factor (P<0.001) for the whole group studied. However, among patients with invasive tumours there was no significant association between the presence of a p53 mutation and a decreased survival. Therefore, patients without a p53 mutation do not necessarily have a good prognosis. There are other features that can lead to an inactive p53 protein, such as complexing with other proteins (Momand et al., 1992) , and other genetic events can occur that result in a poor prognosis. Epidermal growth factor receptor (EGFR) positivity has been shown to be associated with tumour progression and decreased survival (Neal et al., 1990) . Neal et al. also found no significant difference between EGFR positivity and survival among patients with invasive tumours. Furthermore, it has recently been shown that decreased E-cadherin expression correlates with the clinical aggressiveness of bladder cancer (Bringuier et al., 1993) .
The variable order of appearance of genetic alterations in oncogenesis suggests that accumulation, rather than the order of occurrence, is important for tumour progression (Fearon & Vogelstein, 1990) . The increased frequency of allelic loss we find in the tumours with a p53 mutation can lead to tumour progression and poorer prognosis. But, as mentioned above, there are other mechanis which can lead to tumour progression and these may override or bypass the function of p53.
Recently immunohistochemical studies have shown p53 overexpression to be correlated with poor survival (Lipponen, 1993; Sarkis et al., 1993) . In pTl bladder tumours Sarkis et al. (1993) found a clear correlation between nuclear overexpression of p53 protein and disease progression. The study of Lipponen (1993) showed a significant correlation between p53 overexpression and decreased survival for the entire cohort and for the muscle-invasive tumours. However for the pTa and PT1 tumours only a trend was found. In muscle-invasive tumours, we found no association between p53 mutations and decreased survival. This difference stresses again the discordance of p53 immunohistochemistry and p53 mutation analysis (Thompson et al., 1992) . The discrepancy in prognostic value for p53 mutations in superficial disease found in the two immunohistochemical studies might be the result of the use of different antibodies and the scoring system used. We found no p53 mutations in superficial tumours, which might be explained by the relative rarity of grade 3 tumours in this group.
The results of our study indicate that the presence of a p53 mutation is an unfavourable prognostic factor for the whole group studied, but it has no additional prognostic value for the group of muscle-invasive tumours. The step at which p53 mutations occur in the tumour progression cascade of bladder cancer is stfill unclear. In this respect grade 3 superficial tumours deserve more attention. In general, superficial bladder cancer has a good prognosis, but 10-25% of these tumours progress to an invasive stage. Therefore, the correlation between prognosis and p53 mutation in this subgroup is of particular interest.
Furthermore, the discordance of immunohistochemical and p53 mutation analysis indicates that comparative analysis of p53 mutations and overexpression of the p53 oncoprotein in progression of the pTa and pTl tumours is necessary.
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